OBJECTIVES: To determine the cost-effectiveness of open reduction internal fixation (ORIF) of displaced, midshaft clavicle fractures in adults. DESIGN: Formal cost-effectiveness analysis based on a prospective, randomized, controlled trial. SETTING:Eight hospitals in Canada (seven university-affiliated and one community hospital). PATIENTS/PARTICIPANTS: One hundred thirty-two adults with acute, completely displaced, midshaft clavicle fractures. INTERVENTION: Clavicle ORIF versus nonoperative treatment. MAIN OUTCOME MEASUREMENTS: Utilities derived from SF-6D. RESULTS: The base case cost per quality-adjusted life-year (QALY) gained for ORIF was $65,000. Cost-effectiveness improved to $28,150/QALY gained when the functional benefit from ORIF was assumed to be permanent with cost per QALY gained falling below $50,000 when the functional advantage persisted for 9.3 years or more. In other sensitivity analyses, the cost per QALY gained for ORIF fell below $50,000 when ORIF cost less than $10,465 (base case cost $13,668) or the long-term utility difference between nonoperative treatment and ORIF was greater than 0.034 (base case difference 0.014). Short-term disutility associated with fracture healing also affected cost-effectiveness with the cost per QALY gained for ORIF falling below $50,000 when the utility of a fracture treated nonoperatively before union was less than 0.617 (base case utility 0.706) or when nonoperative treatment increased the time to union by 20 weeks (base case difference 12 weeks). CONCLUSIONS: The cost-effectiveness of ORIF after acute clavicle fracture depended on the durability of functional advantage for ORIF compared with nonoperative treatment. When functional benefits persisted for more than 9 years, ORIF had a favorable value compared with many accepted health interventions.
RCT Entities:
OBJECTIVES: To determine the cost-effectiveness of open reduction internal fixation (ORIF) of displaced, midshaft clavicle fractures in adults. DESIGN: Formal cost-effectiveness analysis based on a prospective, randomized, controlled trial. SETTING: Eight hospitals in Canada (seven university-affiliated and one community hospital). PATIENTS/PARTICIPANTS: One hundred thirty-two adults with acute, completely displaced, midshaft clavicle fractures. INTERVENTION: Clavicle ORIF versus nonoperative treatment. MAIN OUTCOME MEASUREMENTS: Utilities derived from SF-6D. RESULTS: The base case cost per quality-adjusted life-year (QALY) gained for ORIF was $65,000. Cost-effectiveness improved to $28,150/QALY gained when the functional benefit from ORIF was assumed to be permanent with cost per QALY gained falling below $50,000 when the functional advantage persisted for 9.3 years or more. In other sensitivity analyses, the cost per QALY gained for ORIF fell below $50,000 when ORIF cost less than $10,465 (base case cost $13,668) or the long-term utility difference between nonoperative treatment and ORIF was greater than 0.034 (base case difference 0.014). Short-term disutility associated with fracture healing also affected cost-effectiveness with the cost per QALY gained for ORIF falling below $50,000 when the utility of a fracture treated nonoperatively before union was less than 0.617 (base case utility 0.706) or when nonoperative treatment increased the time to union by 20 weeks (base case difference 12 weeks). CONCLUSIONS: The cost-effectiveness of ORIF after acute clavicle fracture depended on the durability of functional advantage for ORIF compared with nonoperative treatment. When functional benefits persisted for more than 9 years, ORIF had a favorable value compared with many accepted health interventions.
Authors: Wolfgang C Winkelmayer; Milton C Weinstein; Murray A Mittleman; Robert J Glynn; Joseph S Pliskin Journal: Med Decis Making Date: 2002 Sep-Oct Impact factor: 2.583
Authors: Elliott S Fisher; David E Wennberg; Thérèse A Stukel; Daniel J Gottlieb; F L Lucas; Etoile L Pinder Journal: Ann Intern Med Date: 2003-02-18 Impact factor: 25.391
Authors: C J Clancy; S M Bartsch; M H Nguyen; D R Stuckey; R K Shields; B Y Lee Journal: Eur J Clin Microbiol Infect Dis Date: 2014-02-07 Impact factor: 3.267
Authors: Daniel M Lerman; Matthew G Cable; Patrick Thornley; Nathan Evaniew; Gerard P Slobogean; Mohit Bhandari; John H Healey; R Lor Randall; Michelle Ghert Journal: Clin Orthop Relat Res Date: 2017-03 Impact factor: 4.176
Authors: Laura A Schemitsch; Emil H Schemitsch; Christian Veillette; Rad Zdero; Michael D McKee Journal: Clin Orthop Relat Res Date: 2011-12 Impact factor: 4.176
Authors: Umile Giuseppe Longo; Sughran Banerjee; Julie Barber; Andrew Chambler; Carlos Cobiella; Steven Corbett; Mark Crowther; Steven Drew; Andrea Francis; Marcus Lee; Nicholas Garlick; Iain Packham; Yemi Pearse; Andrew Richards; Chris Roberts; Duncan Tennent; Emily Tims; Philip Michael Ahrens Journal: Trials Date: 2011-02-28 Impact factor: 2.279
Authors: Sylvia A Stegeman; Mireille de Jong; Cornelis F M Sier; Pieta Krijnen; Jan W Duijff; Tom P H van Thiel; Piet A R de Rijcke; Nicolaj M R Soesman; Tjebbe Hagenaars; Freek D Boekhoudt; Mark R de Vries; Gert R Roukema; Andras F K Tanka; Jephta van den Bremer; Hub G W M van der Meulen; Maarten W G A Bronkhorst; Bart A van Dijkman; Stephan W A M van Zutphen; Dagmar I Vos; Niels W L Schep; Martin G Eversdijk; Ger D J van Olden; Johan G H van den Brand; Robert Jan Hillen; Jan Paul M Frölke; Inger B Schipper Journal: BMC Musculoskelet Disord Date: 2011-08-24 Impact factor: 2.362
Authors: Daniel E Axelrod; Seper Ekhtiari; Anthony Bozzo; Mohit Bhandari; Herman Johal Journal: Clin Orthop Relat Res Date: 2020-02 Impact factor: 4.755